Auteurs Guo Y, Dupart M, Irondelle M, Peraldi P, Bost F, Mazure NM
FEBS letters Oct 2024
Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.Auteurs Proteau S, Krossa I, Husser C, Guéguinou M, Sella F, Bille K, Irondelle M, Dalmasso M, Barouillet T, Cheli Y, Pisibon C, Arrighi N, Nahon-Estève S, Martel A, Gastaud L, Lassalle S, Mignen O, Brest P, Mazure NM, Bost F, Baillif S, Landreville S, Turcotte S, Hasson D, Carcamo S, Vandier C, Bernstein E, Yvan-Charvet L, Levesque MP, Ballotti R, Bertolotto C, Strub T
EMBO molecular medicine Aug 2024
Vitiligo auto-immune response upon oxidative stress-related mitochondrial DNA release opens up new therapeutic strategies.Auteurs Sant'Anna-Silva ACB, Botton T, Rossi A, Dobner J, Bzioueche H, Thach N, Blot L, Pagnotta S, Kleszczynski K, Steinbrink K, Mazure NM, Rocchi S, Krutmann J, Passeron T, Tulic MK
Clinical and translational medicine Aug 2024
HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.Auteurs Contenti J, Guo Y, Larcher M, Mirabal-Ortega L, Rouleau M, Irondelle M, Tiroille V, Mazzu A, Duranton-Tanneur V, Pedeutour F, Ben-Sahra I, Lago C, Leva G, Tiberi L, Robert G, Pouponnot C, Bost F, Mazure NM
Cell death discovery Jul 2024
The marine-derived HIF-1α inhibitor, Yardenone 2, reduces prostate cancer cell proliferation by targeting HIF-1 target genes.Auteurs Peng S, Guo Y, Irondelle M, Mazzu A, Kahi M, Ferreira Montenegro P, Bost F, Mazure NM
Cellular & molecular biology letters Jul 2024
Dependence on mitochondrial respiration of malignant T cells reveals a new therapeutic target for angioimmunoblastic T-cell lymphoma.Auteurs Krug A, Mhaidly R, Tosolini M, Mondragon L, Tari G, Turtos AM, Paul-Bellon R, Asnafi V, Marchetti S, Di Mascio L, Travert M, Bost F, Bachy E, Argüello RJ, Fournié JJ, Gaulard P, Lemonnier F, Ricci JE, Verhoeyen E
Cell death discovery Jun 2024
Oxygen shortage: Himalayan adventures in an incubator.Auteurs Mazure NM
The EMBO journal May 2024
The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitntriors.Auteurs Muller C, Lacroix-Malgras V, Kluza J, Laine W, Güler Y, Bost F, Boisbrun M, Mazerbourg S, Flament S
Cancer cell international Apr 2024
Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759.Auteurs Pujalte-Martin M, Belaïd A, Bost S, Kahi M, Peraldi P, Rouleau M, Mazure NM, Bost F
Molecular oncology Jan 2024
The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment.Auteurs Contenti J, Guo Y, Mazzu A, Irondelle M, Rouleau M, Lago C, Leva G, Tiberi L, Ben-Sahra I, Bost F, Mazure NM
Cell death & disease Nov 2023